CHMP positive opinion for new indication of miglustat (Zavesca)

Press release from the CHMP about a new indication for Zavesca (miglustat):

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE POST-AUTHORISATION SUMMARY OF POSITIVE OPINION for
ZAVESCA

International Nonproprietary Name (INN): miglustat
On 18 December 2008  the Committee for Medicinal Products  for Human Use (CHMP) adopted a positive opinion  to  recommend the variation to the terms  of the marketing authorisation  for the medicinal product Zavesca. The Marketing Authorisation Holder for this medicinal product is Actelion Registration Ltd.

The CHMP adopted a new indication as follows: ‘‘treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease’’.

Detailed conditions for the use of this product will be described in the updated Summary of Product Characteristics (SPC) which will be published in  the revised European Public Assessment Report (EPAR) and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

For information, the full indications for Zavesca will be as follows:

‘‘Zavesca is indicated for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease. Zavesca may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.

Zavesca is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease’’.

Source: Human Medicines – CHMP Summaries of Opinion. Miglustat

Illustrated Psychopharmacology Lectures in Your Inbox

  • Mechanisms of action, adverse effects and indications of psychotropic medications.
  • Concise and illustrated presentations. 
  • Practical tips for mental health professionals.

laptop2


 

 

Are you a visual learner interested in learning psychopharmacology? Click here to get our videos